Edgestream Partners L.P. lifted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 242.0% during the second quarter, Holdings Channel.com reports. The fund owned 9,551 shares of the life sciences company’s stock after acquiring an additional 6,758 shares during the period. Edgestream Partners L.P.’s holdings in Illumina were worth $997,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Trivant Custom Portfolio Group LLC lifted its position in Illumina by 166.7% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after acquiring an additional 125 shares during the period. Versant Capital Management Inc raised its stake in shares of Illumina by 292.9% in the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. acquired a new stake in shares of Illumina during the second quarter worth about $34,000. Massmutual Trust Co. FSB ADV boosted its position in Illumina by 86.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock valued at $39,000 after buying an additional 132 shares during the last quarter. Finally, Principal Securities Inc. acquired a new position in Illumina in the 4th quarter worth approximately $51,000. Institutional investors and hedge funds own 89.42% of the company’s stock.
Illumina Stock Performance
Shares of NASDAQ:ILMN opened at $131.20 on Friday. The business’s 50 day moving average price is $125.25 and its 200-day moving average price is $120.57. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a market capitalization of $20.90 billion, a PE ratio of -16.10 and a beta of 1.15. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $148.19.
Wall Street Analyst Weigh In
Several brokerages have commented on ILMN. StockNews.com started coverage on shares of Illumina in a research note on Thursday, August 29th. They set a “buy” rating for the company. UBS Group boosted their target price on shares of Illumina from $131.00 to $133.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Stephens reaffirmed an “overweight” rating and set a $170.00 price target on shares of Illumina in a research report on Wednesday, July 10th. TD Cowen raised Illumina from a “hold” rating to a “buy” rating and boosted their price objective for the company from $126.00 to $144.00 in a report on Wednesday, August 14th. Finally, Robert W. Baird raised their target price on Illumina from $119.00 to $124.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $151.05.
Check Out Our Latest Research Report on ILMN
Illumina Company Profile
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Recommended Stories
- Five stocks we like better than Illumina
- How to Calculate Options Profits
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- What is MarketRank™? How to Use it
- MarketBeat Week in Review – 9/16 – 9/20
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Don’t Miss These 3 Retail Stocks for Fall Gains
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.